Oncopeptides Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Oncopeptides şirketinin toplam hissedar öz sermayesi SEK228.4M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK316.9M ve SEK88.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 251.90m
Eşitlik	SEK 228.42m
Toplam yükümlülükler	SEK 88.46m
Toplam varlıklar	SEK 316.88m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ONCOS 'nin kısa vadeli varlıkları ( SEK296.9M ) kısa vadeli yükümlülüklerini ( SEK84.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: ONCOS şirketinin kısa vadeli varlıkları ( SEK296.9M ) uzun vadeli yükümlülüklerini ( SEK4.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ONCOS borçsuzdur.

Borcun Azaltılması: ONCOS son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ONCOS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ONCOS un, serbest nakit akışı her yıl % 22.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Oncopeptides Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Insufficient new directors

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Insufficient new directors

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Insufficient new directors

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Forecast to breakeven in 2024

Insufficient new directors

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

Insufficient new directors

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Market in the US at This Time

Oncopeptides AB (Publ) Announces Data from Phase 3 Ocean Study Published in the Lancet Haematology

Oncopeptides AB (Publ) Presents Phase 3 Ocean Study Results At the IMW Meeting

Oncopeptides AB (publ) Presents New Data from OCEAN and PORT Study - Abstracts Online

Deputy CEO & CFO recently bought kr82k worth of stock

No longer forecast to breakeven

Oncopeptides' Pepaxto Receives Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care

Forecast to breakeven in 2023

Insider recently bought kr200k worth of stock

Oncopeptides AB Announces Positive Topline Results from the Head-To-Head Phase 3 Ocean Study Evaluating the Efficacy and Safety of Melflufen

Forecast breakeven pushed back to 2024

Oncopeptides AB (Publ) Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting

Oncopeptides AB Completes Patient Enrollment in Phase 2 Port Study

Chief Scientific Officer recently sold kr16m worth of stock

Oncopeptides Announces Commercial Availability of PEPAXTO®

Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.1218 billion.

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Receives U.S. Food and Drug Administration Approval for PEPAXTO for Patients with Relapsed or Refractory Multiple Myeloma

New 90-day high: kr180

Oncopeptides AB (publ) to Report Q2, 2021 Results on Aug 26, 2021

Insider recently sold kr772k worth of stock

Oncopeptides Enrolls the First Patient in the Phase 3 LIGHTHOUSE Combination Study in Multiple Myeloma

Oncopeptides AB Appoints Linda Holmström as Director of Investor Relations

Oncopeptides AB (Publ) Announces That the Pivotal Phase 2 HORIZON Study Evaluating Intravenous Melflufen (INN Melphalan Flufenamide) in Combination with Dexamethasone in Relapsed Refractory Multiple Myeloma, Has Been Published in the Peer-Reviewed Journal of Clinical Oncology

Oncopeptides AB (publ) to Report Q1, 2021 Results on May 26, 2021

Oncopeptides AB (publ) Announces New Data for Melflufen Accepted for Presentation at the Annual American Society of Hematology Meeting

Oncopeptides AB (publ) Submits Investigational New Drug application to FDA for the second drug candidate from the PDC platform

Oncopeptides AB (publ) Intents to File for Conditional Approval of Melflufen with EMA